Research Interests


Above: Acetylcholine EC50 and substance P IC50 of nicotinic acetylcholine receptors for chimeric beta2/beta4 subunits coexpressed with alpha3 in Xenopus oocytes.
Left: Effect of substance P on binding of acetylcholine to nicotinic acetylcholine receptor of Torpedo electroplaque membranes.


Drug and Neurotransmitter Receptor Mechanisms

My general research interest is in the modulation of receptor properties by neurotransmitters and drugs. Currently we are studying the mechanisms of modulation of the nicotinic cholinergic receptor by its neurotransmitter acetylcholine and by the neuropeptide substance P. Nicotinic receptor responsiveness is regulated by acetylcholine and other cholinergic agonists via desensitization. In fact there are several desensitization processes each of which occurs on a different time scale, ranging from milliseconds to several minutes. Nicotinic receptor responsiveness also appears to be regulated physiologically by substance P, an eleven amino acid peptide that inhibits nicotinic receptor activation. One reason we have focused on both of these modulatory mechanisms is that they appear to be interrelated since at least part of the inhibition by substance P seems to be mediated by an increase in the rate and extent of desensitization.

We are studying the molecular bases of these mechanisms using several approaches and techniques. The biochemical properties have been studied on the cellular level by measuring radioactive sodium ion fluxes in neuronal (PC12) and muscle (BC3H1) cell lines. Nicotinic receptor-enriched purified electroplaque membranes have been used to study these processes on a more molecular level using various binding assays and a sodium ion flux assay. Recently we have begun to apply molecular biological methods to determine the structural determinants of agonist-induced desensitization and substance P inhibition, characterizing the properties of various combinations of wild type, chimeric, and mutated neuronal receptor subunits expressed in Xenopus oocytes.

From these studies we have shown that substance P noncompetitively inhibits both neuronal and muscle type nicotinic receptors at submicromolar concentrations. This inhibition appears to be mediated by a direct interaction of the peptide with the receptor at a unique binding site which is distinct from the agonist, neurotoxin, or high affinity local anesthetic binding sites. The mechanism of inhibition is consistent with a combination of a slow allosteric blockade or closing of the receptor channel and a peptide-induced increase in the rate of desensitization. By expressing various combinations of neuronal a and b subunits in Xenopus oocytes we have demonstrated a significant dependence of the apparent affinity of substance P on the b subunit. Using subunit chimeras and specific site mutations two regions of the b subunit were found to contribute to the difference in affinity and the specific amino acids involved have been determined.